Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, i… Read more
Piramal Pharma Limited (PPLPHARMA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.048x
Based on the latest financial reports, Piramal Pharma Limited (PPLPHARMA) has a cash flow conversion efficiency ratio of 0.048x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹3.69 Billion) by net assets (₹77.58 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Piramal Pharma Limited - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Piramal Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Piramal Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Piramal Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PROG HOLDINGS A DL-50
F:AZD
|
N/A |
|
Collegium Pharmaceutical Inc
NASDAQ:COLL
|
0.285x |
|
Brigade Enterprises Limited
NSE:BRIGADE
|
-0.026x |
|
Nordic American Tankers Limited
NYSE:NAT
|
0.008x |
|
Jiangsu Leili Motor Corp Ltd
SHE:300660
|
0.023x |
|
U.S. Physical Therapy Inc
F:UPH
|
0.025x |
|
NORINCO International Cooperation Ltd
SHE:000065
|
0.069x |
|
Hypoport SE
PINK:HYPOF
|
0.014x |
Annual Cash Flow Conversion Efficiency for Piramal Pharma Limited (2021–2025)
The table below shows the annual cash flow conversion efficiency of Piramal Pharma Limited from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹81.25 Billion | ₹8.92 Billion | 0.110x | -13.51% |
| 2024-03-31 | ₹79.11 Billion | ₹10.05 Billion | 0.127x | +77.74% |
| 2023-03-31 | ₹67.73 Billion | ₹4.84 Billion | 0.071x | +87.46% |
| 2022-03-31 | ₹66.97 Billion | ₹2.55 Billion | 0.038x | +350.09% |
| 2021-03-31 | ₹41.01 Billion | ₹347.20 Million | 0.008x | -- |